OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

As you might know, OPKO Health, Inc. (NASDAQ:OPK) recently reported its third-quarter numbers. Revenues of US$174m missed analyst estimates by a little bit, but statutory earnings beat expectations by an impressive , coming in at US$0.03 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for OPKO Health

After the latest results, the consensus from OPKO Health's six analysts is for revenues of US$693.6m in 2025, which would reflect a discernible 2.5% decline in revenue compared to the last year of performance. Per-share losses are expected to explode, reaching US$0.27 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$714.8m and losses of US$0.28 per share in 2025. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for next year.

There was no major change to the US$3.96average price target, suggesting that the adjustments to revenue and earnings are not expected to have a long-term impact on the business. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on OPKO Health, with the most bullish analyst valuing it at US$8.50 and the most bearish at US$2.00 per share. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would also point out that the forecast 2.0% annualised revenue decline to the end of 2025 is better than the historical trend, which saw revenues shrink 7.7% annually over the past five years By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 6.6% per year. So while a broad number of companies are forecast to grow, unfortunately OPKO Health is expected to see its revenue affected worse than other companies in the industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Even so, long term profitability is more important for the value creation process. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for OPKO Health going out to 2026, and you can see them free on our platform here..

You can also view our analysis of OPKO Health's balance sheet, and whether we think OPKO Health is carrying too much debt, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.